Abstract
Background and objective: Physical activity (PA) in obstructive airway diseases (OAD) is likely to be impaired but this has not been extensively studied outside of chronic obstructive pulmonary disease (COPD). We describe PA levels in severe asthma and bronchiectasis compared to moderate–severe COPD and to controls, and tested the cross-sectional associations of PA (steps/day) with shared disease characteristics in the OAD group. Methods: Adults with OAD (severe asthma = 62, COPD = 67, bronchiectasis = 60) and controls (n = 63) underwent a multidimensional assessment, including device-measured PA levels. Results: The OAD group included 189 participants (58.7% females), with median (interquartile range) age of 67 (58–72) years and mean forced expiratory volume in the first second (FEV 1 ) % predicted of 69.4%. Demographic characteristics differed between groups. Compared to controls (52.4% females, aged 55 (34–64) years, median 7640 steps/day), those with severe asthma, bronchiectasis and COPD accumulated less steps/day: median difference of −2255, −2289, and −4782, respectively (P ≤ 0.001). Compared to COPD, severe asthma and bronchiectasis participants accumulated more steps/day: median difference of 2375 and 2341, respectively (P ≤ 0.001). No significant differences were found between the severe asthma and bronchiectasis group. Exercise capacity, FEV 1 % predicted, dyspnoea and systemic inflammation differed between groups, but were each significantly associated with steps/day in OAD. In the multivariable model adjusted for all disease characteristics, exercise capacity and FEV 1 % predicted remained significantly associated. Conclusion: PA impairment is common in OAD. The activity level was associated with shared characteristics of these diseases. Interventions to improve PA should be multifactorial and consider the level of impairment and the associated characteristics.
Original language | English |
---|---|
Pages (from-to) | 352-360 |
Number of pages | 9 |
Journal | Respirology |
Volume | 24 |
Issue number | 4 |
Early online date | 1 Nov 2018 |
DOIs | |
Publication status | Published - 14 Mar 2019 |
Bibliographical note
Funding Information:V.M.M. was supported by an NHMRC TRIP fellowship; has participated in educational symposia funded by GlaxoSmithKline, AstraZeneca, Menarini and Novartis; and has participated in advisory boards for GlaxoSmithKline, AstraZeneca and Menar-ini. P.G.G. holds an NHMRC Practitioner Fellowship; has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis; and has participated in studies funded by GlaxoSmithKline and AstraZe-neca. P.A.G. is supported by a NHMRC-ARC Dementia Research Development Fellowship and has participated in an educational symposium funded by Boehringer Ingelheim.
Funding Information:
The authors would like to thank participants and their families who made this study possible. They are also grateful to Dr Sarah Hiles (PRC for Healthy Lungs, University of Newcastle, Australia) for statistical support, to Kelly Steel, Gabrielle Le Brocq, Amber Smith, Penelope Baines, Dr Netsanet Negewo and Michelle Rostas (PRC for Healthy Lungs, University of Newcastle, Australia) for their assistance and technical support with the study visits; and to the laboratory staff from the PRC for Healthy Lungs for conducting the sample analysis. This research was supported by a University of Newcastle and Priority Research Centre for Healthy Lungs Postgraduate Scholarship and the Hunter Medical Research Institute, Australia.
Funding Information:
The authors would like to thank participants and their families who made this study possible. They are also grateful to Dr Sarah Hiles (PRC for Healthy Lungs, University of Newcastle, Australia) for statistical support, to Kelly Steel, Gabrielle Le Brocq, Amber Smith, Penelope Baines, Dr Netsanet Negewo and Michelle Ros-tas (PRC for Healthy Lungs, University of Newcastle, Australia) for their assistance and technical support with the study visits; and to the laboratory staff from the PRC for Healthy Lungs for conducting the sample analysis. This research was supported by a University of Newcastle and Priority Research Centre for Healthy Lungs Postgraduate Scholarship and the Hunter Medical Research Institute, Australia.
Publisher Copyright:
© 2018 Asian Pacific Society of Respirology